Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $102.80 (15.29% upside)

Current Analysts' Coverage Summary for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetActions
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Cantor FitzgeraldReiterated RatingHold$82.00 -> $86.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2015Roth CapitalSet Price TargetBuy$116.00 -> $127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2015Deutsche BankBoost Price TargetBuy$74.00 -> $94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/21/2014Griffin SecuritiesSet Price Target$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2014Brinson PatrickSet Price Target$98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2014Summer StreetBoost Price TargetBuy$78.00 -> $91.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2014MLV & Co.Boost Price TargetBuy$82.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2013Brean CapitalDowngradeBuy -> Hold$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/26/2013 forward)